Stock comparison
NeuroPace
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
NPCE
NeuroPace
Market cap
$576.87M
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | NPCE | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 32F | 71B | UTHR |
| Benjamin Graham | 75D | 76B | UTHR |
| Philip Fisher | 51C | 76B | UTHR |
| Peter Lynch | 68C | 62C | NPCE |
| Joel Greenblatt | 2F | 46D | UTHR |
| Charlie Munger | 35D | 64C | UTHR |
| Terry Smith | 30F | 64C | UTHR |
Side-by-side metrics
| Metric | NPCE | UTHR |
|---|---|---|
| Market cap | $576.87M | $24.13B |
| P/E (TTM) | - | 19.2x |
| EV/EBIT | - | 15.2x |
| ROIC (TTM) | -19.74% | 18.81% |
| Gross margin | 78.29% | 86.58% |
| Net margin | -14.95% | 40.61% |
| Revenue CAGR 5y | 21.97% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | 4.9x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
NPCE leads on
- P/E (TTM)-vs 19.2x+154%
- EV/EBIT-vs 15.2x+142%
- Revenue CAGR 5y21.97%vs 17.22%+22%
UTHR leads on
- ROIC (TTM)18.81%vs -19.74%+195%
- Net margin40.61%vs -14.95%+137%
- Debt / Equity-vs 4.9x+100%
- Market cap$24.13Bvs $576.87M+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.